For part 3 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the favorable safety and efficacy profile of nipocalimab for generalized myasthenia gravis (gMG).
Our guts are home to trillions of bacteria, and research over the last few decades has established how essential they are to our physiology – in health and disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback